Auto-generated from public data. Not the firm's stated position.
Based on disclosed data, i&i Biotech Fund appears to focus on early-stage biotech and drug discovery companies despite listed sector tags suggesting broader fintech and enterprise exposure. Recent portfolio companies indicate a concentration in therapeutic development and AI-enabled drug discovery, with check sizes ranging from €0.1M to €1.5M across pre-seed through Series B stages.
Generated 6 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from i&i Biotech Fund's website.
PhD in Neuroscience; 10+ years in venture capital leading drug development investments.
PhD in Immunology; several years in venture capital, startup creation, and portfolio management.
25+ years in fund management and VC/PE; oversaw 100+ investments across CEE and the Baltics.
20+ years of leadership in life sciences, pharma, and diagnostics; former CEO of Merck Czech subsidiary.
15+ years in fund management, VC, and PE; expertise in valuations, due diligence, and tax structuring.
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.